Michael S. Eggert
Expertise in
6
conditions

Dr. Michael S. Eggert

Intensive Care Medicine | Pulmonary Medicine
600 Gresham Drive, Suite 8630 B, 
Norfolk, VA 
Accepting New Patients
Offers Telehealth
Expertise in
6
conditions
600 Gresham Drive, Suite 8630 B, 
Norfolk, VA 

Overview

Michael Eggert is an Intensive Care Medicine specialist and a Pulmonary Medicine provider practicing medicine in Norfolk, Virginia.

Dr. Eggert is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Systemic Sclerosis (SSc), and Interstitial Lung Disease.

Dr. Eggert is board certified in American Board Of Internal Medicine - Critical Care Medicine - 2027 and American Board Of Internal Medicine - Pulmonary Disease - 2027. He is actively involved in clinical research, co-authoring 9 peer reviewed articles and participating in 11 clinical trials. Dr. Eggert is currently accepting new patients.

Specialties

Intensive Care Medicine
Pulmonary Medicine

Licenses

Internal Medicine in VA

Board Certifications

American Board Of Internal Medicine - Critical Care Medicine - 2027
American Board Of Internal Medicine - Pulmonary Disease - 2027

Fellowships

UAB Hospital - 2001

Hospital Affiliations

Sentara Norfolk General Hospital
Sentara Virginia Beach General Hospital
Sentara Careplex Hospital
Sentara Obici Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Piedmont
  • HMO
  • POS
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Sentara Pulmonary & Critical Care Specialists - Pulmonary Arterial Hypertension Clinic
600 Gresham Drive, Suite 8630 B, Norfolk, VA 23507

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Enrollment Status: Completed
Publish Date: June 16, 2026
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Terminated
Publish Date: June 11, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
Enrollment Status: Terminated
Publish Date: June 04, 2025
Intervention Type: Drug
Study Phase: Phase 3
An Open-label, Clinical Study to Evaluate the Safety and Tolerability of Treprostinil Inhalation Powder (TreT) in Subjects With Pulmonary Arterial Hypertension Currently Using Tyvaso
An Open-label, Clinical Study to Evaluate the Safety and Tolerability of Treprostinil Inhalation Powder (TreT) in Subjects With Pulmonary Arterial Hypertension Currently Using Tyvaso
Enrollment Status: Completed
Publish Date: November 01, 2024
Intervention Type: Drug
Study Drug: Treprostinil Inhalation Powder
Study Phase: Phase 1
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Biological
Study Drug: Sotatercept
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Enrollment Status: Completed
Publish Date: June 02, 2022
Intervention Type: Drug
Study Drug: UT-15C
Study Phase: Phase 3
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
Enrollment Status: Terminated
Publish Date: November 10, 2020
Intervention Type: Drug
Study Phase: Phase 3
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
Enrollment Status: Terminated
Publish Date: October 22, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
Enrollment Status: Completed
Publish Date: August 03, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

9 Total Publications

BREEZE Optional Extension Phase: Long-term safety and efficacy of treprostinil dry powder inhaler (Tyvaso DPI) in pulmonary arterial hypertension.
BREEZE Optional Extension Phase: Long-term safety and efficacy of treprostinil dry powder inhaler (Tyvaso DPI) in pulmonary arterial hypertension.
Journal: Respiratory medicine
Published: June 18, 2025
Similar Doctors
Expertise in
22
conditions
Dr. Rajiv Gulati
Cardiology | Pulmonary Medicine
Expertise in
22
conditions
Dr. Rajiv Gulati
Cardiology | Pulmonary Medicine
Referral may be required

Mayo Clinic-Rochester

5716 Cleveland St Ste 200, 
Virginia Beach, VA 
 (8.6 miles away)
757-490-4802
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Rajiv Gulati is a Cardiologist and a Pulmonary Medicine provider practicing medicine in Virginia Beach, Virginia. Dr. Gulati is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Spontaneous Coronary Artery Dissection (SCAD), Heart Attack, Coronary Heart Disease, Percutaneous Coronary Intervention (PCI), and Aortic Valve Replacement. Dr. Gulati is currently accepting new patients.

Expertise in
40
conditions
Dr. Carlos A. Silva
Intensive Care Medicine | Pulmonary Medicine | Undersea and Hyperbaric Medicine
Expertise in
40
conditions
Dr. Carlos A. Silva
Intensive Care Medicine | Pulmonary Medicine | Undersea and Hyperbaric Medicine
Referral may be required
Before you request

Virginia Medical Specialists

516 Innovation Drive, Ste 201, 
Chesapeake, VA 
 (9.9 miles away)
757-889-6677
Languages Spoken:
English, Italian, Spanish
See accepted insurances
Accepting New Patients

Carlos Silva is an Intensive Care Medicine specialist and a Pulmonary Medicine provider practicing medicine in Chesapeake, Virginia. Dr. Silva is highly rated in 40 conditions, according to our data. His clinical expertise encompasses Chronic Obstructive Pulmonary Disease (COPD), Lung Metastases, Pulmonary Fibrosis, and Lung Nodules. Dr. Silva is board certified in American Board Of Internal Medicine - Critical Care Medicine - 2027, American Board Of Internal Medicine - Pulmonary Disease - 2027, American Board Of Internal Medicine - Internal Medicine, and American Board Of Preventive Medicine - Undersea And Hyperbaric Medicine - 2031. Dr. Silva is currently accepting new patients.

Expertise in
9
conditions
Dr. Andrew H. Limper
Pulmonary Medicine
Expertise in
9
conditions
Dr. Andrew H. Limper
Pulmonary Medicine
Referral may be required

Mayo Clinic-Rochester

5716 Cleveland St Ste 200, 
Virginia Beach, VA 
 (8.6 miles away)
507-284-2511
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Andrew Limper is a Pulmonary Medicine provider practicing medicine in Virginia Beach, Virginia. Dr. Limper is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Pneumocystis Jiroveci Pneumonia, Pneumonia, Pulmonary Fibrosis, and Idiopathic Pulmonary Fibrosis. Dr. Limper is currently accepting new patients.

Frequently Asked Questions about Dr. Michael S. Eggert

How do I make an appointment with Dr. Michael S. Eggert?

You can book an appointment with Dr. Michael S. Eggert by calling their office at 757-388-9138. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Michael S. Eggert a top-rated expert for Pulmonary Hypertension?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Michael S. Eggert is classified as an Elite expert for Pulmonary Hypertension, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Michael S. Eggert specialize in?

While Dr. Michael S. Eggert is a Intensive Care Medicine, they have specific expertise in Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, and Systemic Sclerosis (SSc). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Intensive Care Medicine.

Does Dr. Michael S. Eggert participate in research or clinical trials?

Yes. Dr. Michael S. Eggert has published 9 articles and abstracts on conditions like Pulmonary Hypertension. You can view a list of Dr. Michael S. Eggert's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Michael S. Eggert accept my insurance?

Dr. Michael S. Eggert accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 757-388-9138 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Eggert's expertise for a condition
ConditionClose
View All 19 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile